Jun 12, 2024
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The...
Jun 12, 2024
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The...
Feb 27, 2024
Dr. Marc Conant, Chief Medical Officer at Addimmune, has been working on HIV/AIDS for over 40 years and highlights the progress that has been made in developing effective HIV drugs. The mission at Addimmune is to develop a functional cure for HIV by modifying the patient's cells to enhance the immune system's ability...
Feb 27, 2024
Dr. Marc Conant, Chief Medical Officer at Addimmune, has been working on HIV/AIDS for over 40 years and highlights the progress that has been made in developing effective HIV drugs. The mission at Addimmune is to develop a functional cure for HIV by modifying the patient's cells to enhance the immune system's ability...
Feb 13, 2024
Wael Hashad, Chief Executive Officer of Longeveron, is focused on developing cell therapy for aging-related conditions such as aging frailty, dementia, and Alzheimer's disease. Using mesenchymal stem cells, also known as medicinal signaling cells, obtained from healthy donors 18-45, Longeveron is seeing...